Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial.
Kraak RP, Tijssen RYG, van Dongen IM, Elias J, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers A, Tijssen JGP, Piek JJ, de Winter RJ, Henriques JPS, Wykrzykowska JJ; Collaborators. Kraak RP, et al. Among authors: tijssen ryg. EuroIntervention. 2020 Dec 4;16(11):e904-e912. doi: 10.4244/EIJ-D-18-00884. EuroIntervention. 2020. PMID: 31062692 Free article.
Implantation techniques (predilatation, sizing, and post-dilatation) and the incidence of scaffold thrombosis and revascularisation in lesions treated with an everolimus-eluting bioresorbable vascular scaffold: insights from the AIDA trial.
Tijssen RYG, Kraak RP, Elias J, van Dongen IM, Kalkman DN, Nassif M, Sotomi Y, Asano T, Katagiri Y, Collet C, Piek JJ, Henriques JPS, de Winter RJ, Tijssen JGP, Onuma Y, Serruys PW, Wykrzykowska JJ. Tijssen RYG, et al. Among authors: tijssen jgp. EuroIntervention. 2018 Jul 20;14(4):e434-e442. doi: 10.4244/EIJ-D-17-01152. EuroIntervention. 2018. PMID: 29688175 Free article. Clinical Trial.
Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI.
Tijssen RYG, Kraak RP, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers A, Elias J, van Dongen IM, Koch KT, Baan J Jr, Vis M, de Winter RJ, Piek JJ, Tijssen JGP, Henriques JPS, Wykrzykowska JJ. Tijssen RYG, et al. Among authors: tijssen jgp. EuroIntervention. 2018 Jul 20;14(4):e426-e433. doi: 10.4244/EIJ-D-18-00335. EuroIntervention. 2018. PMID: 29786537 Free article. Clinical Trial.
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial.
Kerkmeijer LSM, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout KE, Kraak RP, Weevers A, Piek JJ, de Winter RJ, Tijssen JGP, Henriques JPS, Wykrzykowska JJ; Collaborators. Kerkmeijer LSM, et al. Among authors: tijssen ryg. EuroIntervention. 2019 Sep 20;15(7):603-606. doi: 10.4244/EIJ-D-19-00325. EuroIntervention. 2019. PMID: 31147304 Free article. No abstract available.
Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial.
Kerkmeijer LSM, Renkens MPL, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Garcia-Garcia HM, Kraak R, Piek JJ, Tijssen JGP, Henriques JPS, de Winter RJ, Wykrzykowska JJ. Kerkmeijer LSM, et al. Among authors: tijssen ryg. EuroIntervention. 2022 Mar 18;17(16):1340-1347. doi: 10.4244/EIJ-D-21-00419. EuroIntervention. 2022. PMID: 34483094 Free PMC article. Clinical Trial.
Three-year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus-eluting stent in routine PCI in patients with diabetes mellitus-AIDA sub-study.
Kerkmeijer LSM, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Kraak RP, Onuma Y, Serruys PW, Piek JJ, Tijssen JGP, Henriques JPS, de Winter RJ, Wykrzykowska JJ. Kerkmeijer LSM, et al. Among authors: tijssen ryg. Catheter Cardiovasc Interv. 2021 Oct;98(4):713-720. doi: 10.1002/ccd.29329. Epub 2020 Oct 29. Catheter Cardiovasc Interv. 2021. PMID: 33118696 Free PMC article. Clinical Trial.
The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy.
Tijssen RYG, Kerkmeijer LSM, Takahashi K, Kogame N, Katagiri Y, Kraak RP, Chichareon P, Modolo R, Asano T, Nassif M, Kalkman DN, Sotomi Y, Collet C, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Piek JJ, Tijssen JGP, Henriques JP, de Winter RJ, Onuma Y, Serruys PW, Wykrzykowska JJ. Tijssen RYG, et al. Int J Cardiovasc Imaging. 2020 Apr;36(4):565-575. doi: 10.1007/s10554-019-01756-w. Epub 2020 Jan 2. Int J Cardiovasc Imaging. 2020. PMID: 31898006 Clinical Trial.
A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial.
Kerkmeijer LSM, Tijssen RYG, Hofma SH, Pinxterhuis TH, Kraak RP, Kalkman DN, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Beijk MA, Baan J Jr, Vis MM, Koch KT, Tijssen JGP, Piek JJ, Henriques JPS, de Winter RJ, Wykrzykowska JJ. Kerkmeijer LSM, et al. Among authors: tijssen ryg. Int J Cardiol. 2020 Feb 1;300:93-98. doi: 10.1016/j.ijcard.2019.08.045. Epub 2019 Aug 30. Int J Cardiol. 2020. PMID: 31511193 Free article. Clinical Trial.
19 results